摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-异丙基苯基)肼 | 63693-65-2

中文名称
1-(4-异丙基苯基)肼
中文别名
4-异丙基苯肼
英文名称
4-isopropylphenylhydrazine
英文别名
(4-Isopropylphenyl)hydrazine;(4-propan-2-ylphenyl)hydrazine
1-(4-异丙基苯基)肼化学式
CAS
63693-65-2
化学式
C9H14N2
mdl
MFCD00052689
分子量
150.224
InChiKey
ZYATZFJUOXJFPY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    66-69°C
  • 沸点:
    260.1±19.0 °C(Predicted)
  • 密度:
    1.027±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    38
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 安全说明:
    S22,S36/37/39
  • 危险类别码:
    R20/21/22
  • 海关编码:
    2928000090

SDS

SDS:8d588b20bb47cb9099f50e316ab68572
查看
Name: 1-(4-Isopropylphenyl)hydrazine 90+% Material Safety Data Sheet
Synonym:
CAS: 63693-65-2
Section 1 - Chemical Product MSDS Name:1-(4-Isopropylphenyl)hydrazine 90+% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
63693-65-2 1-(4-Isopropylphenyl)hydrazine 90+% unlisted
Hazard Symbols: XN
Risk Phrases: 20/21/22

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 63693-65-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 66 - 69 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H14N2
Molecular Weight: 150

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 63693-65-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Isopropylphenyl)hydrazine - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 63693-65-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 63693-65-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 63693-65-2 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新的2-芳基吡唑并[4,3-c]喹啉衍生物作为有效的和选择性的人A3腺苷受体拮抗剂。
    摘要:
    在本文中,我们报告了新型的2-苯基-2,5-二氢-吡唑并[4,3-c]喹啉-4-酮类化合物作为A(3)腺苷受体拮抗剂的合成和生物学评估。我们设计了一种基于Kira-Vilsmeier反应的新路线,用于合成此类化合物。一些合成的化合物在纳摩尔范围内显示出A(3)腺苷受体亲和力,并在人(h)A(1),A(2A),A(2B)和A(3)的放射性配体结合测定中评估了良好的选择性)腺苷受体亚型。我们在2-苯基环上引入了几个取代基。特别是在4位上被甲基,甲氧基和氯取代可得到最佳活性和选择性6c(K(i)hA(1),A(2A)> 1000 nM,EC(50)hA(2B)> 1000 nM ,K(i)hA(3)= 9 nM),6d(K(i)hA(1),A(2A)> 1000 nM,EC(50)hA(2B)> 1000 nM,K(i)hA (3)= 16 nM),6b(K(i)hA(1),A(2A)> 1000
    DOI:
    10.1021/jm050125k
  • 作为产物:
    描述:
    4-异丙基苯肼盐酸盐 在 sodium hydroxide 作用下, 以 乙醚 为溶剂, 生成 1-(4-异丙基苯基)肼
    参考文献:
    名称:
    苯腙阴离子激发芳基碘化物与醛的光化学羰基化
    摘要:
    光谱研究发现,生成的苯腙阴离子在照射下显着红移至可见光区域进行光活化。光激发的苯腙阴离子有可能减少随后的自由基链反应的芳基碘单电子转移过程。基于苯腙阴离子的特殊光谱特征,开发了芳基碘化物的氧化还原中性光化学羰基化反应。该方案提供了一种方便高效的合成工具,用于在氧化还原中性条件下获得羰基化产物,而不需要过渡金属。
    DOI:
    10.1016/j.cclet.2023.108742
  • 作为试剂:
    描述:
    4-溴苯甲醚苯甲醛1-(4-异丙基苯基)肼 、 cesiumhydroxide monohydrate 作用下, 以 二甲基亚砜 为溶剂, 以36 %的产率得到4-甲氧基二苯甲酮
    参考文献:
    名称:
    苯腙阴离子激发芳基碘化物与醛的光化学羰基化
    摘要:
    光谱研究发现,生成的苯腙阴离子在照射下显着红移至可见光区域进行光活化。光激发的苯腙阴离子有可能减少随后的自由基链反应的芳基碘单电子转移过程。基于苯腙阴离子的特殊光谱特征,开发了芳基碘化物的氧化还原中性光化学羰基化反应。该方案提供了一种方便高效的合成工具,用于在氧化还原中性条件下获得羰基化产物,而不需要过渡金属。
    DOI:
    10.1016/j.cclet.2023.108742
点击查看最新优质反应信息

文献信息

  • An iron(<scp>iii</scp>)-catalyzed dehydrogenative cross-coupling reaction of indoles with benzylamines to prepare 3-aminoindole derivatives
    作者:Wei-Li Chen、Kun Li、Wei-Cong Liao、Wang-Fu Liang、Pei-Wen Qiu、Cui Liang、Gui-Fa Su、Dong-Liang Mo
    DOI:10.1039/d1gc02849a
    日期:——
    excellent yields through an iron(III)-catalyzed dehydrogenative cross-coupling reaction of 2-arylindoles and primary benzylamines under mild reaction conditions. Mechanistic studies show that a cascade reaction involves a tert-butyl nitrite (TBN)-mediated nitrosation of 2-substituted indoles and a 1,5-hydrogen shift to afford indolenine oximes, sequential iron(III)-catalyzed condensation and a 1,5-hydrogen
    我们报告了一种绿色级联方法,通过铁 ( III ) 催化的 2-芳基吲哚和伯苄胺在温和反应条件下的脱氢交叉偶联反应,以良好到优异的产率制备各种 3-氨基吲哚衍生物。机理研究表明,级联反应涉及亚硝酸叔丁酯 (TBN) 介导的 2-取代吲哚的亚硝化和 1,5-氢转移以提供吲哚啉肟、序贯铁 ( III))-催化缩合和 1,5- 氢转移在一锅反应的四个步骤中。该反应显示了吲哚和苄胺的广泛底物范围,并且可以耐受广泛的官能团。此外,反应很容易以克规模进行,反应完成后不会产生废物。3-氨基吲哚产物通过简单的萃取、洗涤和重结晶纯化,无需快速柱色谱。含有3-氨基吲哚单元的双亚胺配体易于一步获得,产率为52%。本方法突出了容易获得的起始材料、简单的纯化程序以及廉价、无毒和环境友好的铁 ( III ) 催化剂的使用。
  • NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS
    申请人:INVENTIVA
    公开号:US20170066717A1
    公开(公告)日:2017-03-09
    The invention relates to compounds of formula (I). where R, R 1 , R 2 , n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.
    这项发明涉及式(I)的化合物。 其中R、R1、R2、n、A和Cy的含义如描述中所示。 式(I)的化合物是Nurr-1调节剂。
  • Divergent Synthesis of 1<i>H</i>-Indazoles and 1<i>H</i>-Pyrazoles from Hydrazones<i>via</i>Iodine-Mediated Intramolecular Aryl and<i>sp</i><sup>3</sup>C-H Amination
    作者:Wei Wei、Zhen Wang、Xikang Yang、Wenquan Yu、Junbiao Chang
    DOI:10.1002/adsc.201700824
    日期:2017.10.4
    by condensation of hydrazines with the corresponding ketones. In the presence of potassium iodide, I2-mediated oxidative cyclization of diaryl and tert-butyl aryl ketone hydrazones produced 1H-indazoles via direct aryl C–H amination. Under similar reaction conditions, primary and secondary alkyl ketone hydrazones were transformed into 1H-pyrazole products in a reaction involving sp3 C–H amination. This
    molecular原子的分子内CH胺的发散已被开发出来,采用分子碘(I 2)作为唯一氧化剂。通过肼与相应的酮的缩合可以容易地获得所需的底物。在碘化钾存在下,二芳基和叔丁基芳基酮aryl的I 2介导的氧化环化反应通过直接芳基CH胺化反应生成1 H-吲唑。在相似的反应条件下,伯和仲烷基酮在涉及sp 3的反应中转化为1 H-吡唑产物。C–H胺化。这种合成方法不涉及过渡金属,并且操作简单,可以高效,可扩展地轻松获得吲唑和吡唑衍生物。
  • Reduction of Hydrazines, Azo and Azoxy Compounds, and Amine N-Oxides with the NiCl2·2H2O–Li–DTBB (cat.) Combination
    作者:Francisco Alonso、Gabriel Radivoy、Miguel Yus
    DOI:10.1016/s0040-4020(00)00797-3
    日期:2000.10
    The NiCl2·2H2O/Li/DTBB (10 mol%) combination allows the reduction of aromatic hydrazines 1 (to amines), azo compounds 2 (to primary amines), azoxy compounds 3 (to azo compounds or to primary amines, depending on the reaction conditions) or amine N-oxides 4 (to tertiary amines), under mild reaction conditions (THF, room temperature).
    通过使用NiCl 2 ·2H 2 O / Li / DTBB(10 mol%)的组合,可以还原芳香肼1(还原为胺),偶氮化合物2(还原为伯胺),偶氮化合物3(还原为偶氮化合物或伯胺), (取决于反应条件)或胺N-氧化物4(成叔胺),在温和的反应条件下(THF,室温)。
  • Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
    申请人:——
    公开号:US20040029875A1
    公开(公告)日:2004-02-12
    A compound of formula (I): 1 wherein: R 1 and R 2 represent hydrogen or a group as defined in the description, R 3 represents hydrogen or alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, R 4 represents a group of formula (II): 2 wherein W and B are as defined in the description, R 5 represents hydrogen or alkyl, A represents a group selected from -A 2 -, -A 1 -A 2 -, -A 2 -A 1 - and -A 1 -A 2 -A 1 -, V is as defined in the description.
    一种化合物的化学式(I): 其中: R1和R2代表氢或描述中定义的基团, R3代表氢或烷基,烯基,炔基,芳基,杂芳基,环烷基或杂环烷基, R4代表化学式(II)的基团: 其中W和B如描述中定义, R5代表氢或烷基, A代表从-A2-,-A1-A2-,-A2-A1-和-A1-A2-A1-中选择的基团, V如描述中定义。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐